enGene (NASDAQ:ENGN) Coverage Initiated at Piper Sandler

Research analysts at Piper Sandler began coverage on shares of enGene (NASDAQ:ENGN) in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The brokerage set an “overweight” rating and a $26.00 price target on the stock. Piper Sandler’s price target indicates a potential upside of 294.54% from the stock’s current price.

A number of other equities analysts also recently commented on ENGN. HC Wainwright began coverage on enGene in a research report on Monday, December 23rd. They set a “buy” rating and a $25.00 price objective for the company. Citizens Jmp raised shares of enGene to a “strong-buy” rating in a research report on Monday, November 18th. Raymond James initiated coverage on shares of enGene in a research report on Wednesday, November 27th. They set an “outperform” rating and a $23.00 price objective for the company. UBS Group cut enGene from a “buy” rating to a “neutral” rating and cut their price target for the company from $34.00 to $7.00 in a research note on Friday, February 14th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $18.00 price objective on shares of enGene in a research report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, enGene has an average rating of “Buy” and a consensus price target of $26.40.

enGene Trading Up 10.4 %

Shares of ENGN stock opened at $6.59 on Tuesday. The stock has a market capitalization of $291.41 million, a P/E ratio of -11.36 and a beta of -0.65. enGene has a fifty-two week low of $4.42 and a fifty-two week high of $18.40. The company has a debt-to-equity ratio of 0.08, a quick ratio of 16.87 and a current ratio of 16.87. The company has a 50 day moving average price of $6.79 and a 200 day moving average price of $7.21.

enGene (NASDAQ:ENGN) last posted its quarterly earnings data on Thursday, December 19th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06. Equities research analysts predict that enGene will post -1.57 EPS for the current fiscal year.

Hedge Funds Weigh In On enGene

A number of hedge funds have recently modified their holdings of the business. Wolverine Asset Management LLC acquired a new stake in shares of enGene during the third quarter worth about $37,000. Vontobel Holding Ltd. purchased a new stake in enGene during the 4th quarter valued at approximately $69,000. Jane Street Group LLC acquired a new stake in enGene during the 4th quarter worth approximately $93,000. Toronto Dominion Bank acquired a new position in shares of enGene in the fourth quarter valued at approximately $97,000. Finally, Cubist Systematic Strategies LLC increased its holdings in shares of enGene by 15.7% in the fourth quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company’s stock valued at $102,000 after purchasing an additional 2,080 shares during the period. 64.16% of the stock is currently owned by hedge funds and other institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.